Nobumasa Hara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nobumasa Hara has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Mikako Tsuchiya
Department of Biochemistry, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
7 shared publicationsHarumi Osago
Department of Biochemistry, Shimane University Faculty of Medicine
3 shared publications- Kazuo Yamada
Department of Biochemistry, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan
3 shared publications Mikiko Kobayashi-Miura
Department of Biochemistry, Shimane University Faculty of Medicine
2 shared publicationsMineyoshi Hiyoshi
Department of Biochemistry, Shimane University Faculty of Medicine
2 shared publications- Takashi Maeno
Keio University
2 shared publications
Latest Publications
- Open Access
- 31 August 2024
- Published by Center for Academic Publications Japan in Journal of Nutritional Science and Vitaminology
- Vol. 70 (4) , 295-304
The Rate of NAD+ Breakdown Is Maintained Constant against Deletion or Overexpression of NAD+-Degrading Enzymes in Mammalian Cells
Cellular NAD+ is continuously degraded and synthesized under resting conditions. In mammals, NAD+ synthesis is primarily initiated from nicotinamide (Nam) by Nam phosphoribosyltransferase, whereas poly(ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2), sirtuin1 (SIRT1), CD38, and sterile alpha and TIR motif containing 1 (SARM1) are involved in NAD+ breakdown. Using flux analysis with 2H-labeled Nam, we found that when mammalian cells were cultured in the absence of Nam, cellular NAD+ levels were maintained and NAD+ breakdown was completely suppressed. In the presence of Nam, the rate of NAD+ breakdown (RB) did not significantly change upon PARP1, PARP2, SIRT1, or SARM1 deletion, whereas stable expression of CD38 did not increase RB. However, RB in PARP1-deleted cells was much higher compared with that in wild-type cells, in which PARP1 activity was blocked with a selective inhibitor. In contrast, RB in CD38-overexpressing cells in the presence of a specific CD38 inhibitor was much lower compared with that in control cells. The results indicate that PARP1 deletion upregulates the activity of other NADases, whereas CD38 expression downregulates the activity of endogenous NADases, including PARP1 and PARP2. The rate of cellular NAD+ breakdown and the resulting NAD+ concentration may be maintained at a constant level, despite changes in the NAD+-degrading enzyme expression, through the compensatory regulation of NADase activity.
- 31 August 2024
- Published by Center for Academic Publications Japan in Journal of Nutritional Science and Vitaminology
- Vol. 70 (4) , 295-304
Open AccessThe Rate of NAD+ Breakdown Is Maintained Constant against Deletion or Overexpression of NAD+-Degrading Enzymes in Mammalian Cells
Cellular NAD+ is continuously degraded and synthesized under resting conditions. In mammals, NAD+ synthesis is primarily initiated from nicotinamide (Nam) by Nam phosphoribosyltransferase, whereas poly(ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2), sirtuin1 (SIRT1), CD38, and sterile alpha and TIR motif containing 1 (SARM1) are involved in NAD+ breakdown. Using flux analysis with 2H-labeled Nam, we found that when mammalian cells were cultured in the absence of Nam, cellular NAD+ levels were maintained and NAD+ breakdown was completely suppressed. In the presence of Nam, the rate of NAD+ breakdown (RB) did not significantly change upon PARP1, PARP2, SIRT1, or SARM1 deletion, whereas stable expression of CD38 did not increase RB. However, RB in PARP1-deleted cells was much higher compared with that in wild-type cells, in which PARP1 activity was blocked with a selective inhibitor. In contrast, RB in CD38-overexpressing cells in the presence of a specific CD38 inhibitor was much lower compared with that in control cells. The results indicate that PARP1 deletion upregulates the activity of other NADases, whereas CD38 expression downregulates the activity of endogenous NADases, including PARP1 and PARP2. The rate of cellular NAD+ breakdown and the resulting NAD+ concentration may be maintained at a constant level, despite changes in the NAD+-degrading enzyme expression, through the compensatory regulation of NADase activity.
- Open Access
- 15 March 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0214000
Quantitative analysis of the effects of nicotinamide phosphoribosyltransferase induction on the rates of NAD+ synthesis and breakdown in mammalian cells using stable isotope-labeling combined with mass spectrometry
NAD+ is mainly synthesized from nicotinamide (Nam) by the rate-limiting enzyme Nam phosphoribosyltransferase (Nampt) and degraded to Nam by NAD+-degrading enzymes in mammals. Numerous studies report that tissue NAD+ levels decrease during aging and age-related diseases and suggest that NAD+ replenishment promotes healthy aging. Although increased expression of Nampt might be a promising intervention for healthy aging, forced expression of Nampt gene, inducing more than 10-fold increases in the enzyme protein level, has been reported to elevate NAD+ levels only 40–60% in mammalian cells. Mechanisms underlying the limited increases in NAD+ levels remain to be determined. Here we show that Nampt is inhibited in cells and that enhanced expression of Nampt activates NAD+ breakdown. Combined with the measurement of each cell’s volume, we determined absolute values (μM/h) of the rates of NAD+ synthesis (RS) and breakdown (RB) using a flux assay with a 2H (D)-labeled Nam, together with the absolute NAD+ concentrations in various mammalian cells including primary cultured cardiomyocytes under the physiological conditions and investigated the relations among total cellular Nampt activity, RS, RB, and the NAD+ concentration. NAD+ concentration was maintained within a narrow range (400–700 μM) in the cells. RS was much smaller than the total Nampt activity, indicating that NAD+ synthesis from Nam in the cells is suppressed. Forced expression of Nampt leading to 6-fold increase in total Nampt activity induced only a 1.6-fold increase in cellular NAD+ concentration. Under the conditions, RS increased by 2-fold, while 2-fold increase in RB was also observed. The small increase in cellular NAD+ concentration is likely due to both inhibited increase in the NAD+ synthesis and the activation of its breakdown. Our findings suggest that cellular NAD+ concentrations do not vary dramatically by the physiological fluctuation of Nampt expression and show the tight link between the NAD+ synthesis and its breakdown.
- 15 March 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0214000
Open AccessQuantitative analysis of the effects of nicotinamide phosphoribosyltransferase induction on the rates of NAD+ synthesis and breakdown in mammalian cells using stable isotope-labeling combined with mass spectrometry
NAD+ is mainly synthesized from nicotinamide (Nam) by the rate-limiting enzyme Nam phosphoribosyltransferase (Nampt) and degraded to Nam by NAD+-degrading enzymes in mammals. Numerous studies report that tissue NAD+ levels decrease during aging and age-related diseases and suggest that NAD+ replenishment promotes healthy aging. Although increased expression of Nampt might be a promising intervention for healthy aging, forced expression of Nampt gene, inducing more than 10-fold increases in the enzyme protein level, has been reported to elevate NAD+ levels only 40–60% in mammalian cells. Mechanisms underlying the limited increases in NAD+ levels remain to be determined. Here we show that Nampt is inhibited in cells and that enhanced expression of Nampt activates NAD+ breakdown. Combined with the measurement of each cell’s volume, we determined absolute values (μM/h) of the rates of NAD+ synthesis (RS) and breakdown (RB) using a flux assay with a 2H (D)-labeled Nam, together with the absolute NAD+ concentrations in various mammalian cells including primary cultured cardiomyocytes under the physiological conditions and investigated the relations among total cellular Nampt activity, RS, RB, and the NAD+ concentration. NAD+ concentration was maintained within a narrow range (400–700 μM) in the cells. RS was much smaller than the total Nampt activity, indicating that NAD+ synthesis from Nam in the cells is suppressed. Forced expression of Nampt leading to 6-fold increase in total Nampt activity induced only a 1.6-fold increase in cellular NAD+ concentration. Under the conditions, RS increased by 2-fold, while 2-fold increase in RB was also observed. The small increase in cellular NAD+ concentration is likely due to both inhibited increase in the NAD+ synthesis and the activation of its breakdown. Our findings suggest that cellular NAD+ concentrations do not vary dramatically by the physiological fluctuation of Nampt expression and show the tight link between the NAD+ synthesis and its breakdown.
- Open Access
- 3 August 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8) , e22781
Nicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma
Nicotinamide (Nam) phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in mammalian NAD synthesis, catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP). NAMPT has also been described as an adipocytokine visfatin with a variety of actions, although physiological significance of this protein remains unclear. It has been proposed that possible actions of visfatin are mediated through the extracellular formation of NMN. However, we did not detect NMN in mouse blood plasma, even with a highly specific and sensitive liquid chromatography/tandem mass spectrometry. Furthermore, there is no or little ATP, the activator of NAMPT, in extracellular spaces. We thus questioned whether visfatin catalyzes the in situ formation of NMN under such extracellular milieus. To address this question, we here determined Km values for the substrates Nam and PRPP in the NAMPT reaction without or with ATP using a recombinant human enzyme and found that 1 mM ATP dramatically decreases Km values for the substrates, in particular PRPP to its intracellular concentration. Consistent with the kinetic data, only when ATP is present at millimolar levels, NAMPT efficiently catalyzed the NMN formation at the intracellular concentrations of the substrates. Much lower concentrations of Nam and almost the absence of PRPP and ATP in the blood plasma suggest that NAMPT should not efficiently catalyze its reaction under the extracellular milieu. Indeed, NAMPT did not form NMN in the blood plasma. From these kinetic analyses of the enzyme and quantitative determination of its substrates, activator, and product, we conclude that visfatin does not participate in NMN formation under the extracellular milieus. Together with the absence of NMN in the blood plasma, our conclusion does not support the concept of “NAMPT-mediated systemic NAD biosynthesis.” Our study would advance current understanding of visfatin physiology.
- 3 August 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8) , e22781
Open AccessNicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma
Nicotinamide (Nam) phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in mammalian NAD synthesis, catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP). NAMPT has also been described as an adipocytokine visfatin with a variety of actions, although physiological significance of this protein remains unclear. It has been proposed that possible actions of visfatin are mediated through the extracellular formation of NMN. However, we did not detect NMN in mouse blood plasma, even with a highly specific and sensitive liquid chromatography/tandem mass spectrometry. Furthermore, there is no or little ATP, the activator of NAMPT, in extracellular spaces. We thus questioned whether visfatin catalyzes the in situ formation of NMN under such extracellular milieus. To address this question, we here determined Km values for the substrates Nam and PRPP in the NAMPT reaction without or with ATP using a recombinant human enzyme and found that 1 mM ATP dramatically decreases Km values for the substrates, in particular PRPP to its intracellular concentration. Consistent with the kinetic data, only when ATP is present at millimolar levels, NAMPT efficiently catalyzed the NMN formation at the intracellular concentrations of the substrates. Much lower concentrations of Nam and almost the absence of PRPP and ATP in the blood plasma suggest that NAMPT should not efficiently catalyze its reaction under the extracellular milieu. Indeed, NAMPT did not form NMN in the blood plasma. From these kinetic analyses of the enzyme and quantitative determination of its substrates, activator, and product, we conclude that visfatin does not participate in NMN formation under the extracellular milieus. Together with the absence of NMN in the blood plasma, our conclusion does not support the concept of “NAMPT-mediated systemic NAD biosynthesis.” Our study would advance current understanding of visfatin physiology.
- 1 January 2010
- Published by Center for Academic Publications Japan in Journal of Nutritional Science and Vitaminology
- Vol. 56 (2) , 83-86
Interferon-γ Elevates Nicotinamide N-Methyltransferase Activity and Nicotinamide Level in Human Glioma Cells
Nicotinamide N-methyltransferase (NNMT) catalyzes the N-methylation of nicotinamide. NNMT is strongly expressed in tumor cells and an increase in NNMT activity may reduce cellular nicotinamide level and thereby promote cell survival in the cells. However, there has been no report of a relationship between NNMT activity and nicotinamide level in tumor cells. We report herein that human glioma cells produce relatively large amounts of NNMT and that when these cells are cultured in the presence of interferon-gamma (IFN-gamma) their 1-methylnicotinamide levels increase. To clarify the mechanisms by which IFN-gamma increases 1-methylnicotinamide levels in these cells, we measured NNMT activity and the levels of NNMT expression, nicotinamide and nicotinamide adenine dinucleotide (NAD(+)) in the presence and absence of IFN-gamma. We also examined whether addition of exogenous 1-methylnicotinamide directly affects cell viability and/or the cellular levels of 1-methylnicotinamide, nicotinamide and NAD(+). While addition of 1-methylnicotinamide increased the total amount of cellular 1-methylnicotinamide present, it did not affect nicotinamide or NAD(+) levels, or cell viability. Conversely, IFN-gamma significantly increased NNMT activity and the nicotinamide cellular concentration, while leaving NNMT expression and the NAD(+) cellular concentration unchanged. Therefore, the increase in the 1-methylnicotinamide level found when IFN-gamma is present in culture may be a consequence of increases in both the nicotinamide concentration and NNMT activity, whereas, 1-methylnicotinamide did not influence nicotinamide levels, NAD(+) levels, or cell viability per se. These results suggest that an increase in NNMT activity does not always reduce cellular nicotinamide concentration in tumor cells.
- 1 January 2010
- Published by Center for Academic Publications Japan in Journal of Nutritional Science and Vitaminology
- Vol. 56 (2) , 83-86
Interferon-γ Elevates Nicotinamide N-Methyltransferase Activity and Nicotinamide Level in Human Glioma Cells
Nicotinamide N-methyltransferase (NNMT) catalyzes the N-methylation of nicotinamide. NNMT is strongly expressed in tumor cells and an increase in NNMT activity may reduce cellular nicotinamide level and thereby promote cell survival in the cells. However, there has been no report of a relationship between NNMT activity and nicotinamide level in tumor cells. We report herein that human glioma cells produce relatively large amounts of NNMT and that when these cells are cultured in the presence of interferon-gamma (IFN-gamma) their 1-methylnicotinamide levels increase. To clarify the mechanisms by which IFN-gamma increases 1-methylnicotinamide levels in these cells, we measured NNMT activity and the levels of NNMT expression, nicotinamide and nicotinamide adenine dinucleotide (NAD(+)) in the presence and absence of IFN-gamma. We also examined whether addition of exogenous 1-methylnicotinamide directly affects cell viability and/or the cellular levels of 1-methylnicotinamide, nicotinamide and NAD(+). While addition of 1-methylnicotinamide increased the total amount of cellular 1-methylnicotinamide present, it did not affect nicotinamide or NAD(+) levels, or cell viability. Conversely, IFN-gamma significantly increased NNMT activity and the nicotinamide cellular concentration, while leaving NNMT expression and the NAD(+) cellular concentration unchanged. Therefore, the increase in the 1-methylnicotinamide level found when IFN-gamma is present in culture may be a consequence of increases in both the nicotinamide concentration and NNMT activity, whereas, 1-methylnicotinamide did not influence nicotinamide levels, NAD(+) levels, or cell viability per se. These results suggest that an increase in NNMT activity does not always reduce cellular nicotinamide concentration in tumor cells.
- 1 June 2007
- Published by Elsevier in Laboratory Investigation
- Vol. 87 (6) , 591-601
FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2
- 1 June 2007
- Published by Elsevier in Laboratory Investigation
- Vol. 87 (6) , 591-601
FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2
- 1 January 2004
- Published by Japanese Association for the Study of Pain in Pain Research
- Vol. 19 (4) , 121-155
Characteristics of µ opioid receptor internalization caused by fentanyl in the rat spinal dorsal horn
- 1 January 2004
- Published by Japanese Association for the Study of Pain in Pain Research
- Vol. 19 (4) , 121-155
Characteristics of µ opioid receptor internalization caused by fentanyl in the rat spinal dorsal horn
- 15 July 2003
- Vol. 63 (14) , 4044-7
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Because the aberrantly activated phosphoinositide 3-kinase (PI3K)/Akt pathway renders tumor cells resistant to cytotoxic insults, including those related to anticancer drugs, inhibition of the pathway may possibly restore or augment the effectiveness of chemotherapy. Using the human malignant glioma cell lines U87, A172, LN18, and LN229, we examined effects of the PI3K inhibitor LY294002 on both apoptosis and cytotoxicity induced by chemotherapeutic agents, including antimicrotubule agents vincristine and paclitaxel, an alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a topoisomerase II inhibitor etoposide, and a DNA cross-linking agent cisplatin (cis-diamminedichloroplatinum), and we compared the LY294002-induced enhancement of effects of those agents. Ten to 20 micro M LY294002 augmented both apoptosis and caspase 3-like activity caused by antimicrotubule agents to a larger extent than induced by 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, and cisplatin in all four malignant glioma cell lines examined. The same doses of LY294002 enhanced cytotoxicity more efficiently with antimicrotubule agents than with other chemotherapeutic agents. Quantitative analyses using a modified isobologram and median effect plot method revealed that enhancement by LY294002 of vincristine- or paclitaxel-induced cytotoxicity was synergistic, whereas enhancement by the PI3K inhibitor of the other chemotherapeutic agent-induced cytotoxicity was additive. Our study indicates that the synergistic augmentation of the cytotoxicity by LY294002 occurs specifically with antimicrotubule agents, at least partially through an increase in caspase 3-dependent apoptosis, and we suggest that inhibitors of the PI3K/Akt pathway in combination with antimicrotubule agents may induce cell death effectively and be a potent modality to treat patients with malignant gliomas.
- 15 July 2003
- Vol. 63 (14) , 4044-7
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Because the aberrantly activated phosphoinositide 3-kinase (PI3K)/Akt pathway renders tumor cells resistant to cytotoxic insults, including those related to anticancer drugs, inhibition of the pathway may possibly restore or augment the effectiveness of chemotherapy. Using the human malignant glioma cell lines U87, A172, LN18, and LN229, we examined effects of the PI3K inhibitor LY294002 on both apoptosis and cytotoxicity induced by chemotherapeutic agents, including antimicrotubule agents vincristine and paclitaxel, an alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a topoisomerase II inhibitor etoposide, and a DNA cross-linking agent cisplatin (cis-diamminedichloroplatinum), and we compared the LY294002-induced enhancement of effects of those agents. Ten to 20 micro M LY294002 augmented both apoptosis and caspase 3-like activity caused by antimicrotubule agents to a larger extent than induced by 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, and cisplatin in all four malignant glioma cell lines examined. The same doses of LY294002 enhanced cytotoxicity more efficiently with antimicrotubule agents than with other chemotherapeutic agents. Quantitative analyses using a modified isobologram and median effect plot method revealed that enhancement by LY294002 of vincristine- or paclitaxel-induced cytotoxicity was synergistic, whereas enhancement by the PI3K inhibitor of the other chemotherapeutic agent-induced cytotoxicity was additive. Our study indicates that the synergistic augmentation of the cytotoxicity by LY294002 occurs specifically with antimicrotubule agents, at least partially through an increase in caspase 3-dependent apoptosis, and we suggest that inhibitors of the PI3K/Akt pathway in combination with antimicrotubule agents may induce cell death effectively and be a potent modality to treat patients with malignant gliomas.
- 23 September 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (9) , 707-712
Molecular study of electron transfer flavoprotein α‐subunit deficiency in two Japanese children with different phenotypes of glutaric acidemia type II
Background Electron transfer flavoprotein is a mitochondrial matrix protein composed of alpha‐ and beta‐subunits (ETFα and ETFβ, respectively). This protein transfers electrons between several mitochondrial dehydrogenases and the main respiratory chain via ETF dehydrogenase (ETF‐DH). Defects in ETF or ETF‐DH cause glutaric acidemias type II (GAII).Materials and methods We investigated the molecular basis of ETFα deficiency in two Japanese children with different clinical phenotypes using expression study.Results Patient 1 had the severe form of GAII, a compound heterozygote of two mutations: 799G to A (αG267R) and nonsense 7C to T (αR3X). Patient 2 had the mild form and carried two heterozygous mutations: 764G to T (αG255V) and 478delG (frameshift). Both patients had one each of missense mutations in one allele; the others were either nonsense or truncated. Restriction enzyme digestion assay using genomic DNAs from 100 healthy Japanese revealed that these mutations were all novel. No signal for ETFα was detected by immunoblotting in cases of missense mutants, while wild‐type cDNA resulted in expression of ETFα protein. Transfection with wild‐type ETFα cDNA into cultured cells from both patients elevated incorporation of radioisotope‐labelled fatty acids.Conclusion These four mutations were pathogenic for GAII and missense mutations, αG255V and αG267R were considered anecdotal for mild and severe forms, respectively.
- 23 September 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (9) , 707-712
Molecular study of electron transfer flavoprotein α‐subunit deficiency in two Japanese children with different phenotypes of glutaric acidemia type II
Background Electron transfer flavoprotein is a mitochondrial matrix protein composed of alpha‐ and beta‐subunits (ETFα and ETFβ, respectively). This protein transfers electrons between several mitochondrial dehydrogenases and the main respiratory chain via ETF dehydrogenase (ETF‐DH). Defects in ETF or ETF‐DH cause glutaric acidemias type II (GAII).Materials and methods We investigated the molecular basis of ETFα deficiency in two Japanese children with different clinical phenotypes using expression study.Results Patient 1 had the severe form of GAII, a compound heterozygote of two mutations: 799G to A (αG267R) and nonsense 7C to T (αR3X). Patient 2 had the mild form and carried two heterozygous mutations: 764G to T (αG255V) and 478delG (frameshift). Both patients had one each of missense mutations in one allele; the others were either nonsense or truncated. Restriction enzyme digestion assay using genomic DNAs from 100 healthy Japanese revealed that these mutations were all novel. No signal for ETFα was detected by immunoblotting in cases of missense mutants, while wild‐type cDNA resulted in expression of ETFα protein. Transfection with wild‐type ETFα cDNA into cultured cells from both patients elevated incorporation of radioisotope‐labelled fatty acids.Conclusion These four mutations were pathogenic for GAII and missense mutations, αG255V and αG267R were considered anecdotal for mild and severe forms, respectively.
- 1 January 1993
- Published by Elsevier in Life Sciences
- Vol. 53 (8) , PL135-PL140
The α1A-Adrenoceptor couples to Ca2+ mobilization in mouse peritoneal macrophages
- 1 January 1993
- Published by Elsevier in Life Sciences
- Vol. 53 (8) , PL135-PL140
The α1A-Adrenoceptor couples to Ca2+ mobilization in mouse peritoneal macrophages
- 1 January 1990
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Physiology
- Vol. 97 (3) , 417-421
Extracellular atp activates ca2+-dependent k+ conductance via ca2+ influx in mouse macrophage
- 1 January 1990
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Physiology
- Vol. 97 (3) , 417-421
Extracellular atp activates ca2+-dependent k+ conductance via ca2+ influx in mouse macrophage